+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effect of cinacalcet on parathyroid hormone level in hypercalcemic hyperparathyroidism of patients with renal transplantation

Effect of cinacalcet on parathyroid hormone level in hypercalcemic hyperparathyroidism of patients with renal transplantation

Medicina Clinica 138(8): 323-326

Cinacalcet reduces parathyroid hormone (PTH) levels in uremic hyperparathyroidism (HPT), and in renal transplantation it is useful in the management of HPT with hypercalcemia. Our main aim is to evaluate if cinacalcet administered once daily, reduces and maintains reduced PTH levels for 24 hours in renal transplant recipients with HPT and hypercalcemia. We studied PTH levels and other bone biomarkers in two groups of renal transplant recipients: one with HPT and hypercalcemia (Group 1), another without alteration of mineral metabolism (Group 2), and a third group of healthy volunteers (Group 3): 35 subjets. Group 1 received a single dose of 60 mg of cinacalcet at 9 am. In all the groups we withdrew blood samples at 8, 10, 11, 12, 13, 19 hours (day 1) and 9 am the following day (day 2), determining levels of PTH and bone biomarkers. In Group 1, basal PTH levels decreased shortly after dispensing cinacalcet (basal PTH level 237 [86.7] versus 10 hour level 113 [54.7] p<0.05), objectifying a progressive increase to a similar level to baseline after 24 hours of the administration (day 2 9h PTH level 241 [117.4] ns). In Group 2, comparisons among PTH mean levels were not different at any time. In Group 3, the mean baseline PTH level was higher than that observed at 10h (47 [22.7] versus 28 [11.2] p<0.05) and other comparisons were not significant. Beta-ctx was higher at baseline in the three groups in comparison with levels at 11, 12, 13 and 19 hour, and similar to that at 10 am on day 1 and 9 am on day 2. With respect to other bone biomarkers, no differences were observed. Cinacalcet administered once daily reduces PTH in renal transplant recipients with HPT and hypercalcemia, without holding it for 24 hours.

(PDF emailed within 0-6 h: $19.90)

Accession: 052799358

Download citation: RISBibTeXText

PMID: 21492884

DOI: 10.1016/j.medcli.2011.01.017

Related references

Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis 19(4): 367-377, 2016

Reelevation of parathyroid hormone level after parathyroidectomy in patients with primary hyperparathyroidism: importance of decreased renal parathyroid hormone sensitivity. Surgery 137(4): 419-425, 2005

Effect of calcium and 1,25 dihydroxyvitamin D on the level of parathyroid hormone in patients with secondary hyperparathyroidism due to chronic renal insufficiency. Medicinski Pregled 46 Suppl 1: 40-42, 1993

Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone. Journal of Bone and Mineral Research 28(3): 700-708, 2013

Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 86(7): 919-924, 2008

Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. American Journal of Nephrology 31(6): 482-489, 2010

Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Mineral and Electrolyte Metabolism 8(2): 92-112, 1982

Long-term clinical practice experience with cinacalcet for treatment of hypercalcemic hyperparathyroidism after kidney transplantation. Biomed Research International 2015: 292654-292654, 2015

Control of bio-intact parathyroid hormone levels with the calcimimetic, cinacalcet HCl, in hemodialysis patients with secondary hyperparathyroidism. Journal of the American Society of Nephrology 14(Abstracts Issue): 462A, November, 2003

The role of intraoperative parathyroid hormone testing in patients with tertiary hyperparathyroidism after renal transplantation. Surgery 138(6): 1066-71; Discussion 1071, 2005

Clinical remission as measured by a decrease in intact parathyroid hormone levels after administration of cinacalcet in patients with severe hyperparathyroidism. Nephrology, Dialysis, Transplantation 23(2): 773-774, 2007

Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. American Journal of Transplantation 8(4): 803-810, 2008

Presence of small parathyroid glands in renal transplant patients supports less-than-total parathyroidectomy to treat hypercalcemic hyperparathyroidism. Surgery 155(1): 22-32, 2014

Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. Clinical Nephrology 76(3): 233-243, 2011

Renal function in patients treated with cinacalcet for persistent hyperparathyroidism after kidney transplantation. Kidney & Blood Pressure Research 34(2): 97-103, 2011